

Health Canada approves Illuccix for prostate cancer imaging

14 October 2022 | News

Illuccix is the first PSMA PET imaging agent to be granted regulatory approval in Canada

Australia's Telix Pharmaceuticals has announced that Health Canada has approved Illuccix [kit for the preparation of gallium (^{68}Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer.

Illuccix [kit for the preparation of gallium (^{68}Ga) gozetotide injection], after radiolabeling with gallium (^{68}Ga), is indicated for use with the positron emission tomography (PET) of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- with suspected metastasis who are suitable for initial definitive therapy
- with suspected recurrence with elevated serum prostate specific antigen (PSA) level.

"PSMA PET" (or the imaging of Prostate-Specific Membrane Antigen (PSMA) via a positron emission tomography (PET) scan) is a diagnostic tool demonstrated to detect advanced prostate cancer.

Illuccix is the first PSMA PET imaging agent to be granted regulatory approval in Canada. Health Canada is the third regulatory body worldwide to approve Illuccix, which is commercially available in Australia and the United States.